Publication number: 20090118499
Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
Type:
Application
Filed:
October 3, 2008
Publication date:
May 7, 2009
Inventors:
Lee D. Arnold, Heather Coate, Andrew Philip Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Michelle Mulvihill, Mark Joseph Mulvihill, Anthony Nigro, Bijoy Panicker, Arno G. Steinig, Quinghua Weng, Douglas S. Werner, Michael J. Wyle, Tao Zhang, Cara Cesario, Yingchuan Sun
Patent number: 7465726
Abstract: Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3?, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Ret, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.
Type:
Grant
Filed:
August 1, 2005
Date of Patent:
December 16, 2008
Assignee:
OSI Pharmaceuticals, Inc.
Inventors:
Saleh Ahmed, Oscar Barba, Jason Bloxham, Graham Dawson, William Gattrell, John Kitchin, Neil Anthony Pegg, Imaad Saba, Shazia Sadiq, Colin Peter Sambrook Smith, Don Smyth, Amo G. Steinig, Robin Wilkes, Bijoy Panicker, Paula Tavares, Matthew Cox, An-Hu Li, Hanqing Dong, Lifu Ma, Kenneth (‘Ken’) Foreman, Qinghua (‘Felix’) Weng, Kathryn Stolz